Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
IPO Year: 1986
Exchange: NASDAQ
Website: repligen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | Peer Perform | Wolfe Research | |
| 8/28/2024 | $180.00 | Overweight | Wells Fargo |
| 6/26/2024 | $180.00 → $155.00 | Hold → Buy | Deutsche Bank |
| 6/18/2024 | Neutral | Guggenheim | |
| 12/4/2023 | Buy → Hold | The Benchmark Company | |
| 7/20/2023 | $185.00 | Overweight | Wells Fargo |
| 7/5/2023 | $220.00 | Overweight | JP Morgan |
| 3/28/2023 | $230.00 | Buy | The Benchmark Company |
| 12/14/2022 | $180.00 | Hold | Deutsche Bank |
| 12/7/2022 | $190.00 | Sector Perform | RBC Capital Mkts |
10-Q - REPLIGEN CORP (0000730272) (Filer)
10-Q/A - REPLIGEN CORP (0000730272) (Filer)
10-Q/A - REPLIGEN CORP (0000730272) (Filer)
10-K/A - REPLIGEN CORP (0000730272) (Filer)
10-Q/A - REPLIGEN CORP (0000730272) (Filer)
10-Q/A - REPLIGEN CORP (0000730272) (Filer)
10-Q/A - REPLIGEN CORP (0000730272) (Filer)
NT 10-Q - REPLIGEN CORP (0000730272) (Filer)
8-K - REPLIGEN CORP (0000730272) (Filer)
8-K - REPLIGEN CORP (0000730272) (Filer)
Third quarter reported revenue of $155 million, an increase of 10% year-over-yearCDMO revenue and orders both up ~20% year-over-yearOverall order intake outpaced sales by 4% Full year revenue guidance narrowed to range of $630-$639 million WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter (Q3) of 2024, covering the three- and nine- month periods ended September 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and access information for today's webcast a
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences. The UBS Global Healthcare Conference being held November 11-14 in Rancho Palos Verdes, CA. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Thursday, November 14, at 10:15 a.m. ET.The Stifel Healthcare Conference being held November 18-19 in New York City. Olivier Loeillot, Chief Executive Officer, and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Tuesday, November 19,
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2024. Olivier Loeillot, President and Chief Executive Officer of Repligen said, "Our team continues to work diligently to complete the required revenue restatements as disclosed on September 18. We plan to file the amended periodic reports related to the required
WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center ("RTIC") at its Waltham headquarters. The opening celebration, held on the evening of September 23, attracted a group of over 150 biopharma and CDMO customers. The RTIC buildout, which features product exhibits, purpose-built demonstration areas and technical training space, was designed to provide customers with pre- and post-sales support, and provide a hands-on experience with Repligen's innovative bioprocessing solutions. The RTIC enables the function
WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen CorporationRepligen Corporation is a global l
Reports second quarter revenue of $154 millionSecond quarter orders of $157 millionBook-to-bill 1.02 for the quarter, 1.01 year-to-dateAchieved first half revenue and order targetsNarrows revenue guidance within previous range for fiscal year 2024; adjusted EPS guidance unchanged WALTHAM, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter (Q2) of 2024, covering the three- and six- month periods ended June 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and acce
Proposed acquisition adds novel macroporous chromatography base bead technology for downstream bioprocess applicationsAccelerates expansion into new modality markets with a unique, scalable purification solutionStrongly synergistic with AVIPure® affinity ligands and OPUS® pre-packed chromatography columns WALTHAM, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Tantti Laboratory Inc. ("Tantti") of Taoyuan City, Taiwan. Tantti has developed a unique portfolio of macroporous chromatography beads to
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of th
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of
Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Purolite's DurA Cycle, a protein A chromatography resin for large-scale purification processes. This new affinity resin is being introduced at the BIO International Convention (BIO 2024), being held June 3-6 in San Diego. This latest innovation marks a significant milestone in Purolite's long-term strategic partnership with Repligen, further solidifying Ecolab's dedication to driving advancements in the bioprocessing industry. DurA Cycle is designed for large-scale commerc
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Deutsche Bank analyst Justin Bowers upgraded the rating for Repligen Corporation (NASDAQ:RGEN) from Hold to Buy, but lowered the price target from $180 to $155. Repligen shares fell 0.4% to close at $123.15 on Tuesday. See how other analysts view this stock. Wolfe Research analyst Steven Chubak upgraded Robinhood Markets, Inc. (NASDAQ:HOOD) from Peer Perform to Outperform, while announcing a price target of $29. Robinhood shares gained 3.6% to close at $22.14 on Tuesday. See how other
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup raised the price target for NVIDIA Corporation (NASDAQ:NVDA) from $126 to $150. Citigroup analyst Atif Malik maintained a Buy rating. NVIDIA shares gained 6.8% to close at $126.09 on Tuesday. See how other analysts view this stock. Truist Securities raised the price target for Rivian Automotive, Inc. (NASDAQ:RIVN) from $10 to $13. Truist Securities analyst Jordan Levy maintained a Hold rating. Rivian Automotive shares gained 8.6% to close at $11.96 on Tuesday. See how other analysts view
Deutsche Bank analyst Justin Bowers upgrades Repligen (NASDAQ:RGEN) from Hold to Buy and lowers the price target from $180 to $155.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Repligen Corp (NASDAQ:RGEN) On June 13, Repligen named Olivier Loeillot as Chief Executive Officer, effective Sept. 1. The co
Guggenheim analyst Subbu Nambi initiates coverage on Repligen (NASDAQ:RGEN) with a Neutral rating.
Shares of Signet Jewelers Limited (NYSE:SIG) fell sharply during Thursday's session following mixed first-quarter earnings including an 8.9% drop in same store sales. The company reported a first-quarter FY25 sales decline of 9.5% year-on-year to $1.510 billion, missing the analyst consensus estimate of $1.514 billion. Adjusted EPS of $1.11 beat the consensus estimates of 85 cents. Signet expects second-quarter sales of $1.46 billion – $1.52 billion, versus the consensus of $1.508 billion. Signet Jewelers shares dipped 12.5% to $94.81 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares climb
Board of Directors approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of Lead Independent Director.
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4/A - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
4 - REPLIGEN CORP (0000730272) (Issuer)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SC 13G - REPLIGEN CORP (0000730272) (Subject)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
Wolfe Research initiated coverage of Repligen with a rating of Peer Perform
Wells Fargo initiated coverage of Repligen with a rating of Overweight and set a new price target of $180.00
Deutsche Bank upgraded Repligen from Hold to Buy and set a new price target of $155.00 from $180.00 previously
Guggenheim initiated coverage of Repligen with a rating of Neutral
The Benchmark Company downgraded Repligen from Buy to Hold
Wells Fargo initiated coverage of Repligen with a rating of Overweight and set a new price target of $185.00
JP Morgan resumed coverage of Repligen with a rating of Overweight and set a new price target of $220.00
The Benchmark Company initiated coverage of Repligen with a rating of Buy and set a new price target of $230.00
Deutsche Bank initiated coverage of Repligen with a rating of Hold and set a new price target of $180.00
RBC Capital Mkts initiated coverage of Repligen with a rating of Sector Perform and set a new price target of $190.00
Third quarter reported revenue of $155 million, an increase of 10% year-over-yearCDMO revenue and orders both up ~20% year-over-yearOverall order intake outpaced sales by 4% Full year revenue guidance narrowed to range of $630-$639 million WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter (Q3) of 2024, covering the three- and nine- month periods ended September 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and access information for today's webcast a
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2024. Olivier Loeillot, President and Chief Executive Officer of Repligen said, "Our team continues to work diligently to complete the required revenue restatements as disclosed on September 18. We plan to file the amended periodic reports related to the required
Reports second quarter revenue of $154 millionSecond quarter orders of $157 millionBook-to-bill 1.02 for the quarter, 1.01 year-to-dateAchieved first half revenue and order targetsNarrows revenue guidance within previous range for fiscal year 2024; adjusted EPS guidance unchanged WALTHAM, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter (Q2) of 2024, covering the three- and six- month periods ended June 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and acce
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six- month reporting periods ended June 30, 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of th
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12% year-over-yearAchieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidance for the full year 2024. Tony J. Hunt, Chief Executive Officer of Repligen said, "We delivered a solid first quarter, with revenue of $151 million and are
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2024 financial results on Wednesday, May 1, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Comp
Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of 1.03 WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023. The company is also providing financial guidance for the full year 2024. Tony J. Hunt, Chief Executive Officer of Repligen said, "During the fourth quarter, we again saw order strength, driven by our Filtration and Analytics franchises and c
WALTHAM, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2023 financial results on Wednesday, February 21, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve-month reporting periods ended December 31, 2023. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations
Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 millionOrders strengthened with total book-to-bill ratio of 1.07 Narrows full year revenue guidance to range of $635-$645 million WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2023, covering the three- and nine-month fiscal periods ended September 30, 2023. Tony J. Hunt, Chief Executive Officer of Repligen said, "While the broader challenges that have dominated our industry over the last twelve months continued i
WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2023 financial results on Tuesday, October 31, 2023. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine-month reporting periods ended September 30, 2023. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen's board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise s
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed Jason K. Garland as Chief Financial Officer ("CFO"), effective September 25, 2023. Mr. Garland is joining Repligen from his most recent role with medical device outsource (MDO) manufacturer Integer Holdings Corporation ("Integer"), where he served for nearly five years (2018-2023) as Executive Vice President and CFO. He succeeds retiring CFO Jon K. Snodgres, who joined the Company in June 2014 and will continue in a full-time advisory role until his October 6, working closely with Mr. Garland to
WALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences tools industry leader Martin D. Madaus. Dr. Madaus brings to the Repligen board over 25 years of industry experience, including five years as Chairman, President and Chief Executive Officer of Millipore Corporation, where he was integral to the company's transformation into a life science leader, and its acquisition by Merck KGaA in 2010. He is an active board leader, currently serving two public companies; as Lead Director for precision health technology company Quanterix Corporation and as Board member for mass cytometry player S
WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Konstantinov brings to the director role nearly 30 years of relevant experience, including his current position as Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. Dr. Konstantinov has been directly involved in the development and commercialization of multiple biotherapeutic modalities, including monoclonal antibodies, blood factors, gene therapy vectors and e
908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo